New company will be called NNE Pharmaplan and expects a EUR200M turnover.
NNE will acquire Pharmaplan, and the new company will be called NNE Pharmaplan. With more than 1,500 employees and sales offices in 15 countries, the companies believe that NNE Pharmaplan will be able to offer an all-encompassing portfolio of consultancy and engineering services in all markets significant to the pharmaceutical industry.
“Our market presence, services, and areas of expertise are complementary,” points out NNE’s president, Hans Ole Voigt. Pharmaplan, a Germany-based engineering company, supplements NNE with know-how in delivery of turnkey facilities, validation, and key pharmaceutical processes. NNE supplements Pharmaplan within areas, such as biotechnology, cleanrooms, and automation. The companies expect that NNE Pharmaplan will have a turnover of more than EUR200 million, as NNE’s turnover in 2005 was EUR163 million and Pharmaplan’s was EUR49 million.
While the companies decided not to disclose the financial terms of the deal, they did report that Pharmatec, a Pharmaplan subsidiary, will not be included in the transaction. Pharmatec manufactures high-quality pure steam, pure water, and sterilization equipment for the pharmaceutical industry. It will be divested at a later date.
The company anticipates the closing of the transaction in the first quarter of 2007. NNE Pharmaplan will be headquartered in Copenhagen and will have a European hub in Pharmaplan’s current offices in Oberursel, Germany. “From here we plan to expand our business into central Europe, which will become an increasingly important market for pharmaceutical and biotechnological companies in the course of the coming years,” remarks Hans Ole Voigt.